Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 637 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... February 21, 2020 FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free September 19, 2019 How I Took Charge of My Cancer Care and Found a... August 30, 2022 Load more HOT NEWS COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen... Tips On Staying Cool During a Heat Wave NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials
